Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $80.00

Palvella Therapeutics (NASDAQ:PVLA) had its target price lifted by Truist Financial from $56.00 to $80.00 in a research note issued to investors on Thursday morning, Marketbeat.com reports. The brokerage currently has a buy rating on the stock.

A number of other equities analysts have also commented on the company. Lifesci Capital started coverage on Palvella Therapeutics in a research note on Monday, August 4th. They issued an “outperform” rating and a $90.00 price objective on the stock. Oppenheimer assumed coverage on Palvella Therapeutics in a report on Tuesday, September 9th. They set an “outperform” rating and a $85.00 price target for the company. Stifel Nicolaus boosted their target price on shares of Palvella Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Chardan Capital increased their price target on shares of Palvella Therapeutics from $60.00 to $73.00 and gave the company a “buy” rating in a report on Friday, September 26th. Finally, HC Wainwright boosted their price objective on shares of Palvella Therapeutics from $75.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Palvella Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $69.27.

Palvella Therapeutics Stock Up 5.0%

NASDAQ:PVLA opened at $65.78 on Thursday. The company’s 50 day moving average is $51.46 and its 200-day moving average is $34.12. Palvella Therapeutics has a 12 month low of $11.17 and a 12 month high of $65.80. The firm has a market cap of $727.53 million, a price-to-earnings ratio of -5.44 and a beta of -0.13.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.08). Research analysts predict that Palvella Therapeutics will post -3.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC acquired a new stake in Palvella Therapeutics in the 4th quarter valued at about $125,000. Clio Asset Management LLC bought a new stake in shares of Palvella Therapeutics during the second quarter valued at approximately $2,063,000. Spire Wealth Management acquired a new stake in shares of Palvella Therapeutics in the first quarter valued at approximately $70,000. Woodline Partners LP bought a new position in Palvella Therapeutics in the 1st quarter worth approximately $5,435,000. Finally, Strid Group LLC acquired a new position in Palvella Therapeutics during the 1st quarter worth $818,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.